Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.

NCT01641107 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

INDUSTRY

Sponsor class

Conditions

Philadelphia Positive
BCR-ABL Positive
Acute Lymphoblastic Leukemia

Interventions

DRUG: Ponatinib

Sponsor

Incyte Corporation